Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20110 in Advanced Solid Tumors
NCT06892379Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of HS-20110 in solid tumor (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose or Maximum Applicable Dose at 1 month and Objective Response Rate at 2 months. Started Feb 2025; status: recruiting.
02
Drugs
HS-20110
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06892379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892379.